Physicians' Academy for Cardiovascular Education

Postive phase II trial data with novel anti-PCSK9 agent

3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein - Hamilton, ON, Canada

EAS 2019 Prof. Evan Stein summarizes novel phase II data of a new 'small binding protein', consisting of adnectin and human albumin, which inhibits PCSK9. The results were such that a phase 3 trial has now started to further study the compound.

Educational information

This video was recorded at the EAS in Maastricht, the Netherlands, on May 29, 2019.

Faculty

Prof. Evan Stein, LIB Therapeutics and Metabolic & Atherosclerosis Research Center, Cincinnati, USA

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Read our summary of new data on the novel anti-PCSK9 agent

Share this page with your colleagues and friends: